Reply to D. Herchenhorn et al

Journal of Clinical Oncology

Volumn 29, Issue 10, 2011, Pages

  Cohen, Ezra E W ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FLUOROURACIL; GEFITINIB; HYDROXYUREA; METHOTREXATE; PACLITAXEL; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN KINASE B BETA; UNCLASSIFIED DRUG; ZALITUMUMAB;

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CARCINOGENESIS; CELLULAR IMMUNITY; DRUG EFFICACY; DRUG SENSITIVITY; DRUG TOLERABILITY; EPITHELIAL MESENCHYMAL TRANSITION; GENE MUTATION; HEAD AND NECK CANCER; HUMAN; IMMUNE RESPONSE; LETTER; LUNG NON SMALL CELL CANCER; NATURAL KILLER CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; STROMA; T LYMPHOCYTE; TREATMENT RESPONSE; TUMOR RECURRENCE;

EID: 79954464575     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.34.1693     Document Type: Letter

References (37)

1. Herchenhorn D, Ferreira CG: Targeting epidermal growth factor receptor to optimize chemoradiotherapy in locally advanced head and neck cancer: Has biology been taken into account? J Clin Oncol 29: e283-e284, 2011
2. Salama JK, Stenson KM, Kistner EO, et al: Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: A multi-institutional phase II trial investigating three radiotherapy dose levels. Ann Oncol 19:1787-1794, 2008
3. Ciardiello F, Tortora G: Epidermal growth factor receptor (EGFR) as a target in cancer therapy: Understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs. Eur J Cancer 39:1348-1354, 2003 (Pubitemid 36773776)
4. Chen LF, Cohen EE, Grandis JR: New strategies in head and neck cancer: Understanding resistance to epidermal growth factor receptor inhibitors. Clin Cancer Res 16:2489-2495, 2010
5. Bonner JA, Harari PM, Giralt J, et al: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567-578, 2006 (Pubitemid 43209104)
6. Vermorken JB, Mesia R, Rivera F, et al: Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359:1116-1127, 2008
7. Burtness B, Goldwasser MA, Flood W, et al: Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: An Eastern Cooperative Oncology Group study. J Clin Oncol 23:8646-8654, 2005 (Pubitemid 46211507)
8. Vermorken JB, Stöhlmacher J, Davidenko I, et al: Primary efficacy and safety results of spectrum, a phase 3 trial in patients (Pts) with recurrent and/or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) receiving chemotherapy with or without panitumumab (Pmab). Presented at the 35th European Society for Medical Oncology Congress, Milan, Italy, October 8-12, 2010
9. Machiels JH, Subramanian S, Ruzsa A, et al: An open-label, randomized, phase III trial of zalutumumab, a human monoclonal EGF receptor (EGFr) antibody, versus best supportive care, in patients with noncurable squamous cell carcinoma (SCCHN) of the head and neck who have failed standard platinumbased chemotherapy (ZALUTE). Presented at the 46th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, June 4-8, 2010
10. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139, 2004 (Pubitemid 38637993)
11. Paez JG, Janne PA, Lee JC, et al: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304:1497-1500, 2004 (Pubitemid 38720929)
12. Cohen EE, Lingen MW, Martin LE, et al: Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR. Clin Cancer Res 11:8105-8108, 2005 (Pubitemid 41698754)
13. Chung CH, Ely K, McGavran L, et al: Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 24:4170-4176, 2006 (Pubitemid 46622295)
14. Temam S, Kawaguchi H, El-Naggar AK, et al: Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol 25:2164-2170, 2007 (Pubitemid 46954638)
15. Koynova DK, Tsenova VS, Jankova RS, et al: Tissue microarray analysis of EGFR and HER2 oncogene copy number alterations in squamous cell carcinoma of the larynx. J Cancer Res Clin Oncol 131:199-203, 2005 (Pubitemid 40175015)
16. Freier K, Joos S, Flechtenmacher C, et al: Tissue microarray analysis reveals site-specific prevalence of oncogene amplifications in head and neck squamous cell carcinoma. Cancer Res 63:1179-1182, 2003 (Pubitemid 36348691)
17. Leonard JH, Kearsley JH, Chenevix-Trench G, et al: Analysis of gene amplification in head-and-neck squamous-cell carcinoma. Int J Cancer 48:511-515, 1991
18. Cohen EE, Haraf DJ, Kunnavakkam R, et al: Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 28:3336-3343, 2010
19. Stewart JS, Cohen EE, Licitra L, et al: Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. J Clin Oncol 27:1864-1871, 2009
20. Sok JC, Coppelli FM, Thomas SM, et al: Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res 12:5064-5073, 2006 (Pubitemid 44453332)
21. Pedrero JM, Carracedo DG, Pinto CM, et al: Frequent genetic and biochemical alterations of the PI 3-K/AKT/PTEN pathway in head and neck squamous cell carcinoma. Int J Cancer 114:242-248, 2005 (Pubitemid 40194293)
22. Murugan AK, Hong NT, Fukui Y, et al: Oncogenic mutations of the PIK3CA gene in head and neck squamous cell carcinomas. Int J Oncol 32:101-111, 2008 (Pubitemid 351176067)
23. Qiu W, Schonleben F, Li X, et al: PIK3CA mutations in head and neck squamous cell carcinoma. Clin Cancer Res 12:1441-1446, 2006
24. Kozaki K, Imoto I, Pimkhaokham A, et al: PIK3CA mutation is an oncogenic aberration at advanced stages of oral squamous cell carcinoma. Cancer Sci 97:1351-1358, 2006 (Pubitemid 44614987)
25. Fenic I, Steger K, Gruber C, et al: Analysis of PIK3CA and Akt/protein kinase B in head and neck squamous cell carcinoma. Oncol Rep 18:253-259, 2007
26. Qiu W, Tong GX, Manolidis S, et al: Novel mutant-enriched sequencing identified high frequency of PIK3CA mutations in pharyngeal cancer. Int J Cancer 122:1189-1194, 2008 (Pubitemid 351214020)
27. Estilo CL, O'Charoenrat P, Ngai I, et al: The role of novel oncogenes squamous cell carcinoma-related oncogene and phosphatidylinositol 3-kinase p110alpha in squamous cell carcinoma of the oral tongue. Clin Cancer Res 9:2300-2306, 2003 (Pubitemid 36687656)
28. Woenckhaus J, Steger K, Werner E, et al: Genomic gain of PIK3CA and increased expression of p110alpha are associated with progression of dysplasia into invasive squamous cell carcinoma. J Pathol 198:335-342, 2002 (Pubitemid 35277384)
29. Poetsch M, Lorenz G, Kleist B: Detection of new PTEN/MMAC1 mutations in head and neck squamous cell carcinomas with loss of chromosome 10. Cancer Genet Cytogenet 132:20-24, 2002 (Pubitemid 34136045)
30. Kalish LH, Kwong RA, Cole IE, et al: Deregulated cyclin D1 expression is associated with decreased efficacy of the selective epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in head and neck squamous cell carcinoma cell lines. Clin Cancer Res 10:7764-7774, 2004 (Pubitemid 39557542)
31. Hatakeyama H, Cheng H, Wirth P, et al: Regulation of heparin-binding EGF-like growth factor by miR-212 and acquired cetuximab-resistance in head and neck squamous cell carcinoma. PLoS ONE 5: e12702, 2010
32. Thomson S, Buck E, Petti F, et al: Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res 65:9455-9462, 2005 (Pubitemid 41508014)
33. Timpson P, Wilson AS, Lehrbach GM, et al: Aberrant expression of cortactin in head and neck squamous cell carcinoma cells is associated with enhanced cell proliferation and resistance to the epidermal growth factor receptor inhibitor gefitinib. Cancer Res 67:9304-9314, 2007 (Pubitemid 47535919)
34. Haddad Y, Choi W, McConkey DJ: Delta-crystallin enhancer binding factor 1 controls the epithelial to mesenchymal transition phenotype and resistance to the epidermal growth factor receptor inhibitor erlotinib in human head and neck squamous cell carcinoma lines. Clin Cancer Res 15:532-542, 2009
35. Cohen EE, Davis DW, Karrison TG, et al: Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: A phase I/II study. Lancet Oncol 10:247-257, 2009
36. Jimeno A, Kulesza P, Wheelhouse J, et al: Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy. Br J Cancer 96:952-959, 2007 (Pubitemid 46452288)
37. Taylor RJ, Chan SL, Wood A, et al: FcgammaRIIIa polymorphisms and cetuximab induced cytotoxicity in squamous cell carcinoma of the head and neck. Cancer Immunol Immunother 58:997-1006, 2009